UNSPSC 51322206: Rosuvastatin zinc

This classification denotes a hmg-coa reductase inhibitor 2C22H27FN3O6S.Zn, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70VE4E19Z7, chemically known as 6-heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, zinc salt (2:1), (3r,5s,6e)-, but more generally known as rosuvastatin zinc, which bears US NIH Compound Identifier 56842257. Most nations, for tariff and trade purposes, schedule rosuvastatin zinc under HS 29350090 and SITC 51580.

UNSPSC 51322206 Rosuvastatin zinc, a Commodity code, covers pharmaceutical active ingredients and finished-form medications procured by state and local health authorities, emergency services, and benefits programs for patient care and public health operations. State and local governments buy rosuvastatin zinc and related statin medications primarily through pharmacy benefit programs, cooperative purchasing alliances, and emergency medical services procurement channels rather than as direct-order commodities. The issuing bodies include state health and human services departments, municipal fire rescue services, multistate cooperative purchasing organizations, and state departments of administration managing pharmaceutical procurement on behalf of enrolled agencies and jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (response date April 8, 2026) to supply Tampa Fire Rescue with four specific emergency medications—labetalol, epinephrine, adenosine, and diltiazem—with an estimated contract value of $40,000 and a one-year initial term plus renewal options; the solicitation carried a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 (response date April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state interest in alternative pharmaceutical distribution channels outside traditional pharmacy benefit managers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (response date March 26, 2026) for generic multi-source pharmaceuticals and OTC products, with awards effective July 1, 2026 and distribution through three authorized wholesalers; the RFP weighted price competitiveness at 75 percent and required vendors to maintain relationships with at least two of the three named wholesalers.